Related Experiment Videos
A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer
Gynecologic Oncology
|January 1, 1986
Abstract:
Twenty-three evaluable patients with refractory epithelial ovarian cancer were treated with bisantrene (CL216,942). The drug was given as a single-dose injection every 3 weeks. One patient (4%) showed a partial response. The compound thus has limited activity against this malignancy.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
MEK inhibitor resistance mechanisms and recent developments in combination trials.
Cancer treatment reviews·2020
Low-grade serous carcinoma of the ovary or peritoneum.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Gynecologic oncology·2015
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010).
European journal of cancer (Oxford, England : 1990)·2014
Incidence and clinical impact of venous thromboembolism during immunotherapy for gynecologic cancer.
Gynecologic oncology·2026
Low-grade serous ovarian cancer: 2026 expert consensus report.
Gynecologic oncology·2026
Therapeutic Potential of Bone Marrow-Derived Mesenchymal Stem Cells in A Letrozole-Induced Rat Model of Polycystic Ovary Syndrome.
International journal of fertility & sterility·2026
CCR1 Antagonism by BX471 Attenuates Neuroinflammation and Apoptosis: Preliminary Findings From an In Vitro Model of Neuronal Injury.
Pharmacology research & perspectives·2026
[Drug sensitivity analysis of monotherapy and combination therapy with Chinese and Western drugs in lung cancer organoid models].
Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026
Central Blockade of Cannabinoid CB1 and CB2 Receptors Increases Force Generation in Reserpine-Treated Mice, but Only CB1 Blockade Extends the Duration of Effort.
ACS pharmacology & translational science·2026